Hospitalisation for venous thromboembolism in cancer patients and the general population: a population-based cohort study in Denmark, 1997-2006

被引:291
|
作者
Cronin-Fenton, D. P. [1 ]
Sondergaard, F. [1 ]
Pedersen, L. A. [1 ]
Fryzek, J. P. [2 ]
Cetin, K. [2 ]
Acquavella, J. [2 ]
Baron, J. A. [3 ,4 ]
Sorensen, H. T. [1 ]
机构
[1] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8200 Aarhus N, Denmark
[2] Amgen Inc, Dept Epidemiol, Thousand Oaks, CA USA
[3] Dartmouth Hitchcock Med Ctr, Dept Community & Family Med, Lebanon, NH 03766 USA
[4] Dartmouth Hitchcock Med Ctr, Dept Med, Lebanon, NH 03766 USA
关键词
incidence rate; venous thromboembolism; epidemiology; treatment; RISK-FACTORS; THROMBOSIS; EPIDEMIOLOGY; REGISTRATION; THALIDOMIDE; DISEASE;
D O I
10.1038/sj.bjc.6605883
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BACKGROUND: Venous thromboembolism (VTE) frequently complicates cancer. Data on tumour-specific VTE predictors are limited, but may inform strategies to prevent thrombosis. METHODS: We computed incidence rates (IRs) with 95% confidence intervals (CIs) for VTE hospitalisation in a cohort of cancer patients (n = 57 591) and in a comparison general-population cohort (n = 287 476) in Denmark. The subjects entered the study in 1997-2005, and the follow-up continued through 2006. Using Cox proportional-hazards regression, we estimated relative risks (RRs) for VTE predictors, while adjusting for comorbidity. RESULTS: Throughout the follow-up, VTE IR was higher among the cancer patients (IR = 8.0, 95% CI = 7.6-8.5) than the general population (IR = 4.7, 95% CI = 4.3-5.1), particularly in the first year after cancer diagnosis (IR = 15.0, 95% CI = 13.8-16.2, vs IR = 8.6, 95% CI = 7.6-9.9). Incidence rates of VTE were highest in patients with pancreas (IR = 40.9, 95% CI = 29.5-56.7), brain (IR = 17.7, 95% CI = 11.3-27.8) or liver (IR = 20.4, 95% CI = 9.2-45.3) tumours, multiple myeloma (IR = 22.6, 95% CI = 15.4-33.2) and among patients with advanced-stage cancers (IR = 27.7, 95% CI = 24.0-32.0) or those who received chemotherapy or no/symptomatic treatment. The adjusted RR (aRR) for VTE was highest among patients with pancreas (aRR = 16.3, 95% CI = 8.1-32.6) or brain cancer (aRR = 19.8 95% CI = 7.1-55.2), multiple myeloma (aRR = 46.1, 95% CI = 13.1-162.0) and among patients receiving chemotherapy, either alone (aRR = 18.5, 95% CI = 11.9-28.7) or in combination treatments (aRR = 16.2, 95% CI = 12.0-21.7). CONCLUSIONS: Risk of VTE is higher among cancer patients than in the general population. Predictors of VTE include recency of cancer diagnosis, cancer site, stage and the type of cancer-directed treatment. British Journal of Cancer (2010) 103, 947-953. doi:10.1038/sj.bjc.6605883 www.bjcancer.com Published online 14 September 2010 (C) 2010 Cancer Research UK
引用
收藏
页码:947 / 953
页数:7
相关论文
共 50 条
  • [41] Population-based survival estimates for childhood cancer in Australia during the period 1997-2006
    Baade, P. D.
    Youlden, D. R.
    Valery, P. C.
    Hassall, T.
    Ward, L.
    Green, A. C.
    Aitken, J. F.
    BRITISH JOURNAL OF CANCER, 2010, 103 (11) : 1663 - 1670
  • [42] Epidemiology of first and recurrent venous thromboembolism: A population-based cohort study in patients without active cancer
    Martinez, Carlos
    Cohen, Alexander T.
    Bamber, Luke
    Rietbrock, Stephan
    THROMBOSIS AND HAEMOSTASIS, 2014, 112 (02) : 255 - 263
  • [43] Hazard of subsequent hematological cancer in patients with incident venous thromboembolism (VTE): A population-based cohort study
    Gangat, Naseema
    Ashrani, Aneel A.
    Petterson, Tanya M.
    Schmoll, Jeffery
    Heit, John A.
    BLOOD, 2007, 110 (11) : 641A - 641A
  • [44] Impact of comorbidity on risk of venous thromboembolism in patients with breast cancer: a Danish population-based cohort study
    Ording, Anne Gulbech
    Horvath-Puho, Erzsebet
    Garne, Jens Peter
    Nystrom, Petra Witt
    Vyberg, Mogens
    Sorensen, Henrik Toft
    Lash, Timothy L.
    BMJ OPEN, 2014, 4 (06):
  • [45] Predictors of venous thromboembolism recurrence and bleeding among active cancer patients: a population-based cohort study
    Chee, Cheng E.
    Ashrani, Aneel A.
    Marks, Randolph S.
    Petterson, Tanya M.
    Bailey, Kent R.
    Melton, L. Joseph, III
    Heit, John A.
    BLOOD, 2014, 123 (25) : 3972 - 3978
  • [46] Validation of clinical risk assessment scores for venous thromboembolism in patients with cancer: a population-based cohort study
    Lanting, Vincent
    Vago, Emese
    Horvath-Puho, Erzsebet
    Mulder, Frits
    Di Nisio, Marcello
    Kamphuisen, Pieter W.
    Pedersen, Lars
    van Es, Nick
    Sorensen, Henrik T.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2025, 23 (02) : 600 - 609
  • [47] Pediatric Venous and Arterial Noncerebral Thromboembolism in Denmark: A Nationwide Population-Based Study
    Tuckuviene, Ruta
    Christensen, Anette L.
    Helgestad, Jon
    Johnsen, Soren P.
    Kristensen, Soren R.
    JOURNAL OF PEDIATRICS, 2011, 159 (04): : 663 - 669
  • [48] Risk of venous thromboembolism in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a general population-based cohort study
    Ogdie, Alexis
    McGill, Neitia Kay
    Shin, Daniel B.
    Takeshita, Junko
    Love, Thorvardur Jon
    Noe, Megan H.
    Fuxench, Zelma C. Chiesa
    Choi, Hyon K.
    Mehta, Nehal N.
    Getfand, Joel M.
    EUROPEAN HEART JOURNAL, 2018, 39 (39) : 3608 - 3614
  • [49] Venous thromboembolism and risk of cancer in users of statins: A Danish population-based cohort study
    Skajaa, Nils
    Nagy, David
    Troelsen, Frederikke Schonfeldt
    Farkas, Dora Kormendine
    Sorensen, Henrik Toft
    THROMBOSIS RESEARCH, 2021, 201 : 1 - 5
  • [50] Venous thromboembolism and risk of cancer in users of statins: A Danish population-based cohort study
    Skajaa, Nils
    Nagy, David
    Troelsen, Frederikke Schonfeldt
    Farkas, Dora Kormendine
    Sorensen, Henrik Toft
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 54 - 54